Eisai

Eisai Co., Ltd. is a leading global research-based pharmaceutical company headquartered in Tokyo, Japan, with a deep-rooted commitment to neurology and oncology. Founded in 1941, the company has evolved into a major international player, known for its pioneering work in Alzheimer’s disease research and its development of innovative treatments for various cancers and neurological conditions. By integrating advanced scientific research with a patient-centric philosophy, Eisai continues to address significant unmet medical needs on a global scale. At the heart of the company’s operations is the 'human health care' (hhc) concept, which prioritizes the needs of patients and their families above all else. This philosophy extends into an 'hhc eco' ecosystem, where the company leverages cutting-edge technology, including artificial intelligence and genetics-guided discovery, to improve the quality of life for individuals worldwide. With a robust portfolio that includes landmark therapies like Leqembi and Lenvima, Eisai remains a cornerstone of the pharmaceutical industry, consistently reinvesting in R&D to drive future medical breakthroughs.

Eisai's mission is to give first thought to patients and people in the daily living domain, striving to increase the benefits that healthcare provides and meet diverse healthcare needs worldwide through its 'human health care' (hhc) philosophy.

• Developed Leqembi, a landmark FDA-approved therapy for early-stage Alzheimer's disease.
• Maintains a long-standing partnership with the WHO to provide free medication for lymphatic filariasis.
• Operates the Center for Genetics Guided Dementia Discovery (G2D2) to accelerate neurological research.
• Consistently invests approximately 23% of annual revenue into research and development.
• Recognized for a unique corporate culture where employees spend 1% of their time with patients.

Sources

• Eisai Official Website
• Eisai US
• Wikipedia